Furthermore, SIRT5-mediated deglutarylation and theconsequent activation of glutamate dehydrogenase 1 (GLUD1) stimulateglutamine catabolism, supporting CRC proliferation (Figure 4).143 In line with this, SIRT5 knockdown in HCT116 and LoVo CRC cell linesled to the inhibition of cell proliferation.143 In addition, CRC cells expressing both SIRT5 and wild-type KRASdisplay resistance to anticancer agents like cetuximab. The gene discussed is SIRT5; the disease is colorectal carcinoma.